secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-268046
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora Q3 net loss $56.8M; cash $171.5M; pipeline updates on NMRA-215, M4 PAMs, NMRA-511
--------------------------------------------------------------------------------

- Net loss of $56.8M for Q3 2025 vs $72.5M in Q3 2024; R&D expense down to $40.5M from $60.6M.
- Cash, equivalents, and marketable securities $171.5M; expects to fund operations into 2027.
- Drew $40M non-dilutive capital from K2 HealthVentures facility.
- NMRA-215 (NLRP3 inhibitor) showed class-leading weight loss in DIO mouse models; Phase 1 expected Q1 2026.
- NMRA-511 Phase 1b data in Alzheimer's agitation expected around year-end; navacaprant KOASTAL topline in 1H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312525268046/0001193125-25-268046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312525268046/nmra-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-268046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer